MYCN and neuroblastoma: Indisulam, a splicing modulator that induces RBM39 degradation, shows strong activity in MNA-NB, including TH-MYCN models, and may enhance anti-GD2 immunotherapy in preclinical studies (Singh et al., 2021; Nijhuis et al., 2022).